drugset / Trial / NCT02539511

Glutamatergic Modulation of Disordered Alcohol Use

NCT02539511 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Alcohol use disorders remain a significant public health problem. The pharmacological facilitation of behavioral treatment represents a promising strategy for addressing disordered drinking. Alcohol use disorders are recognized to be associated with various vulnerabilities that complicate the course of treatment and that may be amenable to glutamate modulators. The purpose of this randomized, double-blind, controlled trial is to test various glutamate modulators in conjunction with motivational enhancement therapy (MET) for alcohol use disorders.

Timeline

Start
2015-07
Primary completion
2017-09
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CI-581a Unknown 0.71 mg/kg Intravenous
Comparator CI-581b Unknown 0.025 mg/kg Intravenous

Indications